This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

GEM - cardiovascular risk module part four - some more difficult clinical cases

Authoring team

(1) A 55 year old lady presents with a history of manic depression. She is on treatment with olanzapine and it has been noted that her weight has increased since initiation of her olanzapine treatment. Recent blood tests revealed a fasting glucose of 6.2 mmol/l. Her fasting lipids revealed a cholesterol level of 7.7 mmol per litre and triglycerides of 4.4 mmol/l. Other secondary causes of hyperlipidaemia were excluded.

  • (a) What is significant about her fasting glucose?
  • (b) Is olanzapine associated with possible development of diabetes?
  • (c) How might olanzapine affect this lady's lipid levels?
  • (d) If this lady was put on simvastatin 40mg per day and her cholesterol was 5.4 mmol/l. What reference is useful in evaluating the efficacy of different statins and deciding the next step in statin treatment ?
  • (e) What is the significance of raised triglyceride in terms of cardiovascular risk?

(2) A 79 year old gentleman has a history of a previous CVA last year. His blood pressure is 130/85 mmHg and his lipid profile shows a cholesterol of 6.5 mmol/l and a TG of 1.3 mmol/l. He has a history of osteoarthritis and hypertension. His current medication is bendroflumethiazide 2.5 mg per day, simvastatin 40mg per day, aspirin 75 mg per day, ibuprofen and omeprazole.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.